Regeneron Stock Undervalued, Says Barclays with $923 Target

Barclays Initiates Positive Coverage on Regeneron

Barclays has initiated coverage on Regeneron Pharmaceuticals with an Overweight rating, setting a price target of $923 per share. The financial services firm stated that the company's current stock price undervalues its growth potential.

Undervalued Potential of Dupixent

The brokerage's analysis highlights that investors are underestimating the near and medium-term profit growth from Dupixent. Barclays suggests that new clinical indications for the drug could sustain its double-digit annual sales increases. The potential of Regeneron's broader drug pipeline was also noted as a key strength.

Market and Stock Implications

This optimistic rating could boost investor confidence in Regeneron's stock. The analysis points to a valuation gap, suggesting the market has not fully priced in the long-term value of the company's primary pharmaceutical assets. This could attract further investment and potentially drive the share price toward the new target.

Summary and Outlook

Looking forward, market participants will likely focus on Dupixent's sales figures and progress on its new applications. The successful expansion of its use is a critical factor for achieving the projected growth and validating Barclays' positive assessment.

FAQ

Q: Why did Barclays issue an Overweight rating for Regeneron?
A: Barclays believes the market undervalues the sustained profit growth from its key drug, Dupixent, and the potential of its future drug pipeline.

Q: What is the price target set by Barclays for Regeneron stock?
A: Barclays has set a price target of $923 for Regeneron Pharmaceuticals.

Source: Investing.com